Adam S. Crystal - Department of Microbiology, University of Pennsylvania School of Medicine

基本信息

浏览量：35

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 73 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Evaluation of the Impact of Homozygous MTAP Truncations on the Activity and Selectivity of MTA-cooperative PRMT5 Inhibitors

Matthew R. Tonini, Andre A. Mignault,Douglas A. Whittington, Steven A. Lombardo,Binzhang Shen,Hannah Stowe,Satoshi Yoda,Shangtao Liu,Minjie Zhang,Kevin M. Cottrell,Samuel R. Meier, Heidi Rego,Jennifer Morawiak,Ellen Hooper,Yi Yu,Heather DiBenedetto,Adam S. Crystal, Teng,Kimberly Briggs

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Supplementary Figure 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Komal Jhaveri,Dejan Juric,Yoon-Sim Yap,Sara Cresta, Rachel M. Layman, Francois P. Duhoux,Catherine Terret,Shunji Takahashi, Jens Huober,Nicole Kundamal,Qing Sheng,Alejandro Balbin, Yan Ji, Wei He,Adam Crystal,Serena De Vita,Giuseppe Curigliano

crossref（2024）

引用0浏览0引用

Supplement 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors

Matthew R. Tonini, Andre A. Mignault,Douglas A. Whittington, Steven A. Lombardo,Binzhang Shen,Hannah Stowe, Satoshi Yoda,Shangtao Liu,Minjie Zhang,Kevin M. Cottrell,Samuel R. Meier, Heidi Rego,Jennifer Morawiak,Ellen Hooper,Yi Yu,Heather DiBenedetto,Adam S. Crystal, Teng,Kimberly Briggs

Cancer Researchno. 6_Supplement (2024): 4631-4631

引用0浏览0引用

Supplementary Figure 7 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

Supplementary Figure 3 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

Supplement 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

Supplementary Information from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

Supplementary Figure 6 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

crossref（2024）

引用0浏览0引用

TNG348 is Synergistic with PARP Inhibitors in Tumor Models with Elevated Replication Stress

Antoine Simoneau,Hsin-Jung Wu,Charlotte Pratt, Grace Comer,Shangtao Liu,Samuel Meier,Tenzing Khendu,Ashley Choi,Hongxiang Zhang, Binzhang Shen,Douglas Whittington,Sirimas Sudsakorn, Wenhai Zhang,Yi Yu,Yingnan Chen,Brian Haines,Adam Crystal,Jannik N. Andersen,John Maxwell,Scott Throner

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn